These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
3298 related items for PubMed ID: 10353251
1. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ. Nature; 1999 May 20; 399(6733):271-5. PubMed ID: 10353251 [Abstract] [Full Text] [Related]
2. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH. J Biol Chem; 2000 Aug 18; 275(33):25733-41. PubMed ID: 10823831 [Abstract] [Full Text] [Related]
3. Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing. Mole DR, Maxwell PH, Pugh CW, Ratcliffe PJ. IUBMB Life; 2001 Jul 18; 52(1-2):43-7. PubMed ID: 11795592 [Abstract] [Full Text] [Related]
4. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. Tanimoto K, Makino Y, Pereira T, Poellinger L. EMBO J; 2000 Aug 15; 19(16):4298-309. PubMed ID: 10944113 [Abstract] [Full Text] [Related]
5. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH. Oncogene; 2000 Nov 16; 19(48):5435-43. PubMed ID: 11114720 [Abstract] [Full Text] [Related]
6. Identification of novel VHL target genes and relationship to hypoxic response pathways. Maina EN, Morris MR, Zatyka M, Raval RR, Banks RE, Richards FM, Johnson CM, Maher ER. Oncogene; 2005 Jun 30; 24(28):4549-58. PubMed ID: 15824735 [Abstract] [Full Text] [Related]
7. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. Pugh CW, Ratcliffe PJ. Semin Cancer Biol; 2003 Feb 30; 13(1):83-9. PubMed ID: 12507560 [Abstract] [Full Text] [Related]
8. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer. Maynard MA, Ohh M. Am J Nephrol; 2004 Feb 30; 24(1):1-13. PubMed ID: 14654728 [Abstract] [Full Text] [Related]
9. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH, Ratcliffe PJ, Maher ER. Hum Mol Genet; 2001 May 01; 10(10):1029-38. PubMed ID: 11331613 [Abstract] [Full Text] [Related]
10. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER. Cancer Res; 2002 Jul 01; 62(13):3803-11. PubMed ID: 12097293 [Abstract] [Full Text] [Related]
11. Dynamic, site-specific interaction of hypoxia-inducible factor-1alpha with the von Hippel-Lindau tumor suppressor protein. Yu F, White SB, Zhao Q, Lee FS. Cancer Res; 2001 May 15; 61(10):4136-42. PubMed ID: 11358837 [Abstract] [Full Text] [Related]
12. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin WG. Hum Mol Genet; 2001 May 01; 10(10):1019-27. PubMed ID: 11331612 [Abstract] [Full Text] [Related]
13. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor. Baba M, Hirai S, Yamada-Okabe H, Hamada K, Tabuchi H, Kobayashi K, Kondo K, Yoshida M, Yamashita A, Kishida T, Nakaigawa N, Nagashima Y, Kubota Y, Yao M, Ohno S. Oncogene; 2003 May 08; 22(18):2728-38. PubMed ID: 12743597 [Abstract] [Full Text] [Related]
14. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Wykoff CC, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ. Oncogene; 2000 Dec 14; 19(54):6297-305. PubMed ID: 11175344 [Abstract] [Full Text] [Related]
15. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma. Clifford SC, Astuti D, Hooper L, Maxwell PH, Ratcliffe PJ, Maher ER. Oncogene; 2001 Aug 16; 20(36):5067-74. PubMed ID: 11526493 [Abstract] [Full Text] [Related]
16. Regulation of STRA13 by the von Hippel-Lindau tumor suppressor protein, hypoxia, and the UBC9/ubiquitin proteasome degradation pathway. Ivanova AV, Ivanov SV, Danilkovitch-Miagkova A, Lerman MI. J Biol Chem; 2001 May 04; 276(18):15306-15. PubMed ID: 11278694 [Abstract] [Full Text] [Related]
17. HIF-1-dependent transcriptional activity is required for oxygen-mediated HIF-1alpha degradation. Berra E, Richard DE, Gothié E, Pouysségur J. FEBS Lett; 2001 Feb 23; 491(1-2):85-90. PubMed ID: 11226425 [Abstract] [Full Text] [Related]
18. The pVHL-hIF-1 system. A key mediator of oxygen homeostasis. Maxwell PH, Pugh CW, Ratcliffe PJ. Adv Exp Med Biol; 2001 Feb 23; 502():365-76. PubMed ID: 11950150 [Abstract] [Full Text] [Related]
19. The von Hippel-Lindau tumor suppressor gene. Kondo K, Kaelin WG. Exp Cell Res; 2001 Mar 10; 264(1):117-25. PubMed ID: 11237528 [Abstract] [Full Text] [Related]